The tests will be available for HCA patients who meet screening criteria, according to an Oct. 17 press release. HCA’s affiliate, the Nashville-based Sarah Cannon Cancer Institute, will lead the Grail test partnership.
The Galleri test is the first clinically validated test that can detect shared cancer signals across more than 50 types of cancer using a blood draw.
HCA is also participating in an interventional study of the Galleri test in Nashville, Denver, Austin, Texas, and Asheville, N.C.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
